- Home
- PIII vs PMN Comparison
PIII vs PMN Comparison
Compare PIII & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- PMN
- Stock Information
- Founded
- PIII 2015
- PMN 2004
- Country
- PIII United States
- PMN Canada
- Employees
- PIII N/A
- PMN N/A
- Industry
- PIII Medical/Nursing Services
- PMN Pharmaceuticals and Biotechnology
- Sector
- PIII Health Care
- PMN Health Care
- Exchange
- PIII Nasdaq
- PMN Nasdaq
- Market Cap
- PIII 21.4M
- PMN 16.0M
- IPO Year
- PIII N/A
- PMN N/A
- Fundamental
- Price
- PIII $6.23
- PMN $0.40
- Analyst Decision
- PIII Buy
- PMN Strong Buy
- Analyst Count
- PIII 2
- PMN 2
- Target Price
- PIII $16.25
- PMN $4.50
- AVG Volume (30 Days)
- PIII 3.7K
- PMN 63.7K
- Earning Date
- PIII 08-06-2025
- PMN 08-07-2025
- Dividend Yield
- PIII N/A
- PMN N/A
- EPS Growth
- PIII N/A
- PMN N/A
- EPS
- PIII N/A
- PMN N/A
- Revenue
- PIII $1,485,192,000.00
- PMN N/A
- Revenue This Year
- PIII N/A
- PMN N/A
- Revenue Next Year
- PIII $6.01
- PMN N/A
- P/E Ratio
- PIII N/A
- PMN N/A
- Revenue Growth
- PIII 9.79
- PMN N/A
- 52 Week Low
- PIII $6.00
- PMN $0.38
- 52 Week High
- PIII $32.54
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- PIII 42.33
- PMN 32.23
- Support Level
- PIII $6.00
- PMN $0.48
- Resistance Level
- PIII $6.46
- PMN $0.50
- Average True Range (ATR)
- PIII 0.21
- PMN 0.03
- MACD
- PIII 0.07
- PMN -0.01
- Stochastic Oscillator
- PIII 33.33
- PMN 18.75
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.